AnaptysBio, Inc. (ANAB) NASDAQ

66.11

-0.48(-0.72%)

Updated at April 28 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Daniel R. Faga	President, Chief Executive Officer & Director	1.2M	1980
Dennis Mulroy	Chief Financial Officer	673,635	1955
Eric J. Loumeau	Chief Legal Officer	722,002	1963
Paul F. Lizzul FAAD	Chief Medical Officer	795,198	1975
Martin Dahl	Senior Vice President of Research	0	N/A
John Kwon	Vice President of GI Clinical Development	0	N/A
Benjamin Stone	Chief Business Officer	0	1991
David McKeon	Senior Vice President & Controller	0	1972
Beth Mueller	Senior Vice President of Human Resources	0	N/A
Cailin Sibley FACR	Senior Vice President of Translational Medicine	0	N/A
Monique Da Silva	Senior Vice President of Corporate Affairs	0	N/A
Priya Raina	Senior Vice President of Clinical Operations	0	N/A

Name

Title

Pay

Year Born

Daniel R. Faga

President, Chief Executive Officer & Director

1.2M

1980

Dennis Mulroy

Chief Financial Officer

673,635

1955

Eric J. Loumeau

Chief Legal Officer

722,002

1963

Paul F. Lizzul FAAD

Chief Medical Officer

795,198

1975

Martin Dahl

Senior Vice President of Research

N/A

John Kwon

Vice President of GI Clinical Development

N/A

Benjamin Stone

Chief Business Officer

1991

David McKeon

Senior Vice President & Controller

1972

Beth Mueller

Senior Vice President of Human Resources

N/A

Cailin Sibley FACR

Senior Vice President of Translational Medicine

N/A

Monique Da Silva

Senior Vice President of Corporate Affairs

N/A

Priya Raina

Senior Vice President of Clinical Operations

N/A

Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.